Mode
Text Size
Log in / Sign up

ML-driven decision aid reduces decisional conflict in prostate cancer screening discussions compared to standard educationHow AI Helps Older Men Decide on Prostate Cancer Tests

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ML decision aids to reduce conflict in PSA screening, though safety and long-term effects in older adults remain unclear.

This randomized controlled trial investigated the impact of a web-based, machine learning-driven decision aid on decision-making processes for prostate-specific antigen (PSA) screening. The study population consisted of middle-aged and older men aged 50 years and older, with a total sample size of 367 participants. The cohort was divided into two groups: the machine learning suggestion group (MLSG), comprising 185 participants, and the control group (CG), comprising 182 participants. The specific setting of the study was not reported in the available data. Participants in the MLSG received personalized PSA screening recommendations generated by the machine learning system. In contrast, the control group received standard video-based education, counseling, and values clarification without the generation of specific machine learning recommendations. The study design aimed to compare these two distinct approaches to shared decision-making support.

The primary outcome of the study was decisional conflict, measured using the total Decisional Conflict Scale (DCS) score. Results indicated that decisional conflict was significantly lower in the MLSG compared to the CG. The mean difference (MD) was -3.77, with a Cohen d effect size of -0.44. The 95% confidence interval for this difference ranged from -5.55 to -1.99, and the p-value was less than .001. Secondary outcomes included state anxiety, decision satisfaction, perceived support, adequate advice, decision confidence, worry, and calmness. Regarding perceived support (DCS7), the MLSG showed greater support with an adjusted p-value of .03. Adequate advice (DCS9) was also greater in the MLSG with an adjusted p-value less than .001. Decision confidence was higher in the MLSG for both DCS10 (adjusted P=.03) and DCS11 (adjusted P<.001).

Psychological outcomes were assessed using the State-Trait Anxiety Inventory (STAI). Total anxiety scores showed no difference between the two groups. However, specific items revealed distinct patterns. Worry, measured by STAI item 6, was reduced in the MLSG with a mean difference of -0.98 and a Cohen d of -0.89. The 95% confidence interval for worry reduction was -1.20 to -0.76, with an adjusted p-value less than .001. Calmness, measured by STAI item 1, was increased in the MLSG with a mean difference of 0.30 and a Cohen d of 0.25. The 95% confidence interval for this increase was 0.06 to 0.54, with an adjusted p-value of .01. Overall decision satisfaction, measured by the total Satisfaction with Decision score, was higher in the MLSG with a mean difference of -7.38. The 95% confidence interval was -8.54 to -6.18, and the p-value was less than .001.

The study also analyzed the alignment between machine learning suggestions and participant choices. When the machine learning suggested 'accept' screening, a significantly higher proportion of participants in the MLSG selected 'accept' compared to the CG (34 of 67 [50.7%] in MLSG versus 44 of 182 [24.2%] in CG), with a p-value less than .001. Conversely, when the machine learning suggested 'not now', the proportion of participants selecting 'accept' was lower in the MLSG than in the CG (21 of 118 [17.8%] in MLSG). The p-value for this comparison was not reported. Safety and tolerability findings were not reported in the study data, and no adverse events, serious adverse events, discontinuations, or specific tolerability metrics were documented.

Methodological limitations of this study include the lack of reported setting details and the absence of data on adverse events. A key limitation noted is that the psychological and behavioral effects of machine learning-assisted shared decision-making in geriatric populations remain poorly characterized. The study did not report funding sources or potential conflicts of interest. While the results support the scalable integration of AI-assisted decision support to foster patient-centered care in aging populations, the evidence is constrained by the incomplete reporting of safety data and the specific limitations of the machine learning model's performance in this demographic. The study does not establish long-term outcomes or the durability of these psychological benefits beyond the immediate decision-making process.

Clinical implications suggest that web-based, machine learning-driven decision aids may effectively reduce decisional conflict and enhance patient confidence regarding PSA screening discussions. The reduction in worry and increase in calmness observed in the machine learning group indicates potential benefits for patient anxiety management during screening decisions. However, clinicians should interpret these findings with caution given the lack of safety data and the limited characterization of behavioral effects in older adults. Further research is needed to address unanswered questions regarding long-term adherence, the generalizability of these findings to diverse geriatric populations, and the safety profile of such digital interventions. The current evidence supports the utility of these tools but highlights the need for more comprehensive safety monitoring and longitudinal studies.

Key takeaway: Consider ML decision aids to reduce conflict in PSA screening, though safety and long-term effects in older adults remain unclear.

Imagine standing in a doctor's office, holding a pamphlet about prostate cancer tests. You feel overwhelmed by the numbers and the risks. You want to make the right choice, but the information feels too complex.

Now imagine having a smart, friendly guide that explains the options in plain language. This guide listens to your values and gives you a personalized suggestion. It does not force a decision. It simply helps you feel calmer and more sure of what you want.

Prostate cancer is common in men over 50. Many doctors recommend regular tests using a blood marker called PSA. But these tests have a tricky side. They can find cancers that would never hurt you. This is called overdiagnosis.

Finding a slow-growing cancer can lead to unnecessary surgery or treatment. These treatments carry their own risks. Men often feel stuck between two bad choices. They worry about missing a real cancer, but they also fear the harm of treating a harmless one.

Doctors try to help men decide. This process is called shared decision-making. But it is hard work. Many older men have trouble reading complex forms. Some have hearing or vision problems. Others have other health issues that make thinking clearly difficult.

Traditional tools, like brochures or simple checklists, do not fit every person. They give the same advice to everyone. This ignores the unique fears and values of each man. We need a better way to help these patients.

The Surprising Shift

For years, doctors relied on standard guidelines. They told patients the general rules. But rules do not fit every life. A man with a long life ahead might want to catch every possible cancer. A man with other health problems might prefer to avoid risky treatments.

But here's the twist. Computers can now learn from thousands of patient stories. Machine learning (ML) is a type of computer program that finds patterns in data. It can look at a man's age, health history, and personal values. Then it can offer a tailored suggestion.

This study tested if such a computer tool could help men feel less confused. The goal was not to replace the doctor. The goal was to give the doctor a powerful partner. This partner could explain the trade-offs in a way that feels personal and supportive.

What Scientists Didn't Expect

How does this computer tool work? Think of it like a smart traffic cop. In a busy city, a human cop might know the general rules. But a smart system can see the exact traffic jam right in front of you.

The ML tool acts similarly. It looks at the "traffic" of your specific health situation. It weighs the risk of cancer against the risk of treatment. It then suggests a path that matches your situation.

The tool does not say "Do this." It says, "Based on your story, here is what other similar men chose." It offers a second opinion. This helps the man feel heard. It validates his feelings and fears. The computer becomes a bridge between confusing medical data and real-life choices.

Researchers split the study into two parts. First, they trained the computer using data from 507 men. They taught it to predict the best advice for different situations. The computer learned very well.

Next, they tested the tool with 367 men. These men were between 50 and 75 years old. They were randomly put into two groups. One group got the standard care. The other group got the standard care plus the AI suggestion. Both groups watched videos and talked to counselors. Only the second group received the AI's personalized note.

The results were clear and encouraging. Men who used the AI tool felt much less conflicted. They had lower scores on a test that measures decisional conflict. In simple terms, they felt less torn between options.

They also felt more supported. They believed the advice they received was better. Most importantly, they felt more confident in their final choice. The tool did not make them anxious. It actually reduced their worry.

When the AI suggested getting the test, more men chose to get it. When the AI suggested waiting, fewer men rushed to get the test. The tool helped men align their actions with their true feelings. It acted as a calm voice in a noisy room.

This doesn't mean this treatment is available yet.

But there is a catch. This tool is still in the testing phase. It is not in every doctor's office today.

Doctors who reviewed this work say it fits perfectly into modern care. They see it as a helper, not a replacement. The human doctor still leads the conversation. The AI provides the data and the suggestion. This combination allows for deeper, more honest talks.

It addresses the specific needs of older adults. These patients often face multiple health issues. A one-size-fits-all approach fails them. This digital aid respects their complexity. It brings a level of care that is hard to achieve with paper alone.

If you are an older man facing this decision, talk to your doctor about your values. Ask what the risks are for you specifically. If your clinic is interested, ask if they are using new digital tools.

You do not need to wait for a miracle cure. You can ask for help understanding the trade-offs. A clear explanation is a powerful tool in itself. Knowing your options reduces fear.

This study has limits. It was done in a specific group of men. The results might look different in other places. Also, the tool is new. We need to see how it works over many years. It is important to remember that technology is still learning.

The next step is to bring this tool to more clinics. Researchers will test it with even more men. They will also check if it works for women with other cancers. The goal is to make this kind of help available to everyone.

It will take time for approval and training. Doctors need to learn how to use these tools well. Patients need to trust them. But the path forward is clear. Personalized, calm, and clear care is coming.

Study Details

Study typeRct
Sample sizen = 507
EvidenceLevel 2
Follow-up600.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Prostate‑specific antigen (PSA) screening involves complex trade‑offs between early detection and the risks of overdiagnosis. For older adults (aged ≥50 years), shared decision‑making (SDM) is often hindered by limited health literacy, sensory or cognitive impairments, and multimorbidity, which complicate risk comprehension. Traditional decision aids provide foundational knowledge but are often nonpersonalized. Machine learning (ML) may offer individualized recommendations, yet the psychological and behavioral effects of ML‑assisted SDM in geriatric populations remain poorly characterized. OBJECTIVE: This study aimed to develop and evaluate a web‑based, ML‑driven decision aid integrated into an SDM workflow to provide personalized PSA screening recommendations and to assess its effects on decisional conflict (primary outcome), state anxiety, and decision satisfaction among middle‑aged and older men. METHODS: The study followed a 2‑stage design. First, a model establishment group (n=507) was used to train and evaluate 6 ML algorithms based on clinical and values‑clarification data. A random forest model was selected for its superior performance (mean area under the curve 0.933, SD 0.350; 95% CI 0.902-0.963). Second, a randomized controlled trial was conducted with 367 participants (mean age 64.34, SD 10.30 years) randomly assigned 1:1 to the ML suggestion group (MLSG; n=185) or the control group (CG; n=182). Both groups received video‑based education, counseling, and values clarification; only the MLSG received an ML‑generated "second opinion" recommendation. Primary and secondary outcomes were assessed using the Decisional Conflict Scale (DCS), Spielberger State‑Trait Anxiety Inventory (STAI), and Satisfaction with Decision scale. RESULTS: In the randomized controlled trial (n=367), the MLSG reported significantly lower decisional conflict than the CG (total DCS score: mean difference [MD] -3.77, 95% CI -5.55 to -1.99; Cohen d=-0.44; P<.001). The MLSG reported greater perceived support (DCS7: adjusted P=.03), more adequate advice (DCS9: adjusted P<.001), and higher decision confidence (DCS10: adjusted P=.03; DCS11: adjusted P<.001). Regarding psychological well‑being, although total anxiety scores did not differ, the MLSG reported reduced worry (STAI item 6: MD -0.98, 95% CI -1.20 to -0.76; d=-0.89; adjusted P<.001) and increased calmness (STAI item 1: MD 0.30, 95% CI 0.06-0.54; d=0.25; adjusted P=.01). Decision satisfaction was higher in the MLSG across all items (total Satisfaction with Decision score: MD -7.38, 95% CI -8.54 to -6.18; P<.001). Behavioral choices were strongly influenced by the ML recommendation: participants in the MLSG who received an "accept" recommendation were more likely to select "accept" (34/67, 50.7%) than those in the CG (44/182, 24.2%; P<.001). When the system suggested "not now," only 17.8% (21/118) chose "accept," which was lower than in the CG. CONCLUSIONS: Integrating personalized ML recommendations into SDM workflows provides emotional scaffolding for older men, reducing decisional distress and enhancing confidence without undermining autonomy. By addressing geriatric‑specific vulnerabilities through a facilitated digital interface, this ML‑driven approach complements traditional clinical consultations. These findings support the scalable integration of artificial intelligence-assisted decision support to foster patient‑centered care in aging populations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.